| Dr Annette M Hughes, MD | |
|
9307 W 148th Pl, Overland Park, KS 66221-9374 | |
| (913) 685-8200 | |
| Not Available |
| Full Name | Dr Annette M Hughes |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 35 Years |
| Location | 9307 W 148th Pl, Overland Park, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396058905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2016011272 (Missouri) | Primary |
| 207R00000X | Internal Medicine | 04-26539 (Kansas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Saint Lukes North Hospital | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
News Archive
Over 650,000 Europeans are killed every year because they smoke, one in seven of all deaths across the EU, and over 13 million more are suffering from a serious, chronic disease as a result of their smoking.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.
The Healthcare Trends Institute, an educational platform for employers, consumers and other healthcare benefits stakeholders, has announced its first annual HealthDifference™ Awards.
One of the few studies of its type has found that a startling 59 percent of college students at one Oregon university were "food insecure" at some point during the previous year, with possible implications for academic success, physical and emotional health and other issues.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 4 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20031111000818 |
News Archive
Over 650,000 Europeans are killed every year because they smoke, one in seven of all deaths across the EU, and over 13 million more are suffering from a serious, chronic disease as a result of their smoking.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.
The Healthcare Trends Institute, an educational platform for employers, consumers and other healthcare benefits stakeholders, has announced its first annual HealthDifference™ Awards.
One of the few studies of its type has found that a startling 59 percent of college students at one Oregon university were "food insecure" at some point during the previous year, with possible implications for academic success, physical and emotional health and other issues.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Annette M Hughes, MD 901 E 104th St, Kansas City, MO 64131-4517 Ph: (816) 502-8752 | Dr Annette M Hughes, MD 9307 W 148th Pl, Overland Park, KS 66221-9374 Ph: (913) 685-8200 |
News Archive
Over 650,000 Europeans are killed every year because they smoke, one in seven of all deaths across the EU, and over 13 million more are suffering from a serious, chronic disease as a result of their smoking.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.
The Healthcare Trends Institute, an educational platform for employers, consumers and other healthcare benefits stakeholders, has announced its first annual HealthDifference™ Awards.
One of the few studies of its type has found that a startling 59 percent of college students at one Oregon university were "food insecure" at some point during the previous year, with possible implications for academic success, physical and emotional health and other issues.
HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."
› Verified 4 days ago
Dr. Kirstin Claire Hirni, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5701 W 119th St Ste 220, Overland Park, KS 66209 Phone: 913-498-8787 Fax: 913-498-1744 | |
Mohammad Alghalith, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10500 Quivira Rd, Overland Park, KS 66215 Phone: 913-541-3543 | |
Jonathan T. Jacobs, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 5701 W 119th St Ste 419, Overland Park, KS 66209 Phone: 913-498-1444 Fax: 913-667-2759 | |
Dr. Aimee Nicole Eidson, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5701 W 119th St, Suite 220, Overland Park, KS 66209 Phone: 913-498-8787 Fax: 913-498-1744 | |
Dr. Lary Bocquin, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 7100 College Blvd, Overland Park, KS 66210 Phone: 877-456-5506 | |
Joseph Stilwill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12140 Nall Ave, Ste 200, Overland Park, KS 66209 Phone: 913-498-7409 Fax: 913-541-5028 |